COVID vaccinations: questions and answers about the rollout in North Yorkshire - NHS North Yorkshire CCG
Coronavirus information
Patients recruitment | Patients retention | Cromos Pharma
Virology Research Clinic - University of Washington
Safety and immunogenicity of seven COVID-19 vaccines as a third dose ( booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV- BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine | NEJM
How To Improve Patient Recruitment In Clinical Trials? | Credevo Articles
Antibody persistence and immune memory response following primary vaccination and boosting with live attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) in Bangladesh: A phase 4 open-label clinical trial - ScienceDirect
Home | COV-Boost
PRACT: a pragmatic randomized adaptive clinical trial protocol to investigate a culturally adapted brief negotiational intervention for alcohol use in the emergency department in Tanzania | Trials | Full Text
Pfizer seeks authorization for new Covid booster, without fresh clinical data
Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel
UK volunteers to receive Moderna Omicron COVID-19 booster vaccine in clinical study | NIHR
Volunteers needed for expanded COVID-19 booster trial | KPWHRI
Virology Research Clinic - University of Washington
Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial - eBioMedicine
NIH begins clinical trial evaluating second COVID-19 booster shots in adults | National Institutes of Health (NIH)
NIH clinical trial evaluating Moderna COVID-19 variant vaccine begins | National Institutes of Health (NIH)
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial | Nature Medicine
Vaccines
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial - The Lancet
COVID-19 Boosters: Why You Should Schedule One Now
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial - The Lancet Infectious Diseases
Ongoing booster vaccine trial seeks vaccinated volunteers | Newsroom
A Bivalent Omicron-Containing Booster Vaccine against Covid-19 | NEJM
